Leadership team

Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO founded in 2012 from intellectual property licensed from Washington University. Fimbrion’s mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including antibiotic-resistant strains.

 
 
Headshot_Hannan_small_cropped.jpg

Thomas J. Hannan, DVM, PhD
Chief Scientific Officer
Part-Time Faculty Appointment, Research Instructor in Pathology and Immunology, Washington University School of Medicine

  • 23 Peer-Reviewed Publications in UTI Pathophysiology, Bacterial Pathogenesis, and Urogenital Mucosal Immunity

  • NIH Mucosal Immunology Studies Team Young Scholar

  • Expertise in Animal Models of Infection, e.g. UTI, and Pre-Clinical Drug Development

  • Principal Investigator, NIH Phase I and II Small Business Innovation Research (SBIR) Grants